Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Authors
Keywords
BI 10773, Diabetes, Empagliflozin, Pharmacodynamics, Pharmacokinetics, Safety, Tolerability
Journal
Diabetes Therapy
Volume 4, Issue 2, Pages 331-345
Publisher
Springer Nature
Online
2013-07-09
DOI
10.1007/s13300-013-0030-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects
- (2013) Stephan A. Veltkamp et al. CLINICAL DRUG INVESTIGATION
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- Learning From Glycosuria: FIG. 1.
- (2011) Ele Ferrannini DIABETES
- Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
- (2011) S. Sha et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
- Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus
- (2011) Sherwyn L. Schwartz et al. Diabetes Technology & Therapeutics
- Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
- (2011) James F. List et al. KIDNEY INTERNATIONAL
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
- (2010) L. Zhang et al. DIABETES OBESITY & METABOLISM
- Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis
- (2010) G. Schernthaner et al. DIABETOLOGIA
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Renal glucose transporters: novel targets for hyperglycemia management
- (2010) Amanda Mather et al. Nature Reviews Nephrology
- Diabetes Prevalence and Therapeutic Target Achievement in the United States, 1999 to 2006
- (2009) Bernard M.Y. Cheung et al. AMERICAN JOURNAL OF MEDICINE
- Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects
- (2009) W. T. CEFALU et al. CLEVELAND CLINIC JOURNAL OF MEDICINE
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
- (2009) J. P.H. Wilding et al. DIABETES CARE
- Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
- (2009) J. E. Gerich DIABETIC MEDICINE
- Therapeutic targets to reduce cardiovascular disease in type 2 diabetes
- (2009) Cyrus DeSouza et al. NATURE REVIEWS DRUG DISCOVERY
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now